Batista N et al. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004;90(9):1740-6. Abstract

Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract

Di Costanzo F et al. Weekly paclitaxel plus capecitabine in advanced breast cancer patients: Dose-finding trial of GOIRC and GOL. Ann Oncol 2006;17(1):79-84. Abstract

El-Helw L, Coleman RE. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005;14(5):368-74. Abstract

Friedrich M et al. Taxanes in the first-line chemotherapy of metastatic breast cancer: Review. Eur J Gynaecol Oncol 2004;25(1):66-70. Abstract

Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7. Abstract

Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: Retrospective analysis of patients treated at MD Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Kaklamani V, O’Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004;31(2 Suppl 4):20-5. Abstract

Mackey JR et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004;5(4):287-92. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract

Pagani O et al. Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer. Ann Oncol 2005;16(10):1609-17. Abstract

Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist. 2004;(9 Suppl 1):43-9. Abstract

Susnjar S et al. Weekly paclitaxel (TAX) and capecitabine (CAP) for metastatic breast cancer (MBC) patients (PTS) previously treated with anthracycline-containing therapy: A phase I dose-finding study. Proc ASCO 2005;Abstract 851.

Tubiana-Hulin M. How to maximize the efficacy of taxanes in breast cancer. Cancer Treat Rev 2005;31(Suppl 4):3-9. Abstract

Uhlmann C et al. Capecitabine with weekly paclitaxel for advanced breast cancer: A phase I dose-finding trial. Oncology 2004;67(2):117-22. Abstract

Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005;27(1):23-44. Abstract